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AntioxidantAbstract The cross talk between the over expression of oxygen-free radicals is known as reactive
oxygen species (ROS) that is associated with the excessive telomerase activity (TA). Telomerase
activity is an invariable ﬁnding where human telomerase (hTERT) has been implicated in tumor
oxidative stress and redox-mediated malignancy. The hTERT over expression is a novel tumor mar-
ker and is promising as a novel class of therapeutic weapons to ﬁght against cancer.
A new series of phenylene diamines were designed, synthesized, and evaluated for their in vitro
antioxidant as an indicator of inhibiting the oxidative stress tumor. Compounds 3b and 7b proved
to be the most active antioxidants with high percentage ABTS inhibition ranged from 89.40% to
88.59% respectively. Molecular modeling studies indicated that the crest conﬁguration of phenylene
diamine nucleus with substitutions of trimethoxy benzamido functional proved to be crucial for
enhancing the free radical scavenging activity. Molecular modeling exploration indicated the proper
binding selectivity of the 3b and 7b to the 3KYL pocket with promising hTERT inhibitors as a hall-
mark of cancer.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
Reactive oxygen species (ROS) are generated by normal cellu-
lar processes, environmental stresses, and UV irradiation. ROS
react with cellular components, damaging DNA, carbohy-
drates, proteins, and lipids causing cellular and tissue injury.
The generation of ROS is a consequence of aerobic life and is
unavoidable. ROS represent a constant source of assaults upon
our genetic material which can be either enhanced or partly re-
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(Sebastia´n et al., 2009; Liu et al., 2010; Salmon et al., 2004).
At the normal level, non-cancer cells are able to protect
themselves against oxidative DNA damage, via natural antiox-
idant defense mechanisms to guard against prolonged, exces-
sive levels of ROS by scavenging excessive levels of ROS
with enhancement of DNA repair because ROS can react
chemically with different proteins and other elements of a cell,
altering their normal function. Overproduction and cumula-
tive production of ROS through either endogenous or exoge-
nous insults are harmful to living organisms and are
common for many types of cancer cell that are linked with al-
tered redox regulation of cellular signaling pathways. Oxida-
tive stress can induce a cellular redox imbalance causing
serious damage to a cell and shut off immune functions leading
to the development and progression of oxidative DNA damage
inducing oxidative stress tumor. ROS are known not only to
attack DNA, but also additional cellular components such as
proteins and lipids, leaving behind reactive species that can,
in turn, couple to DNA bases leading to DNA lesion that
serves as a biomarker of carcinogenesis (Jomova et al., 2010).
Antioxidants are believed to be important in health mainte-
nance through the modulation of oxidative processes in the
body (Mosca et al., 2002). Oxidative damage with the unregu-
lated production of ROS has been implicated in a growing list
of clinical disorders such as atherosclerosis, rheumatoid arthri-
tis, stroke, cataract, Parkinson’s disease, Alzheimer’s disease
and cancer (Valko et al., 2006). Mechanisms responsible for
the ROS mediated injury to cells and tissues mainly include
lipid peroxidation, protein oxidation, and oxidative DNA
damage as a cascade of tumor evolution that is accompanied
with over expression of hTRT (Shukla et al., 2011). This back-
ground has stimulated interest in the possibility of design and
synthesis of a new antioxidant to serve as a tool to selectively
inhibit the oxidative DNA damage and control the progression
of the tumors that were mediated by over expression telome-
rase enzyme (Poszaj et al., 2010).
1.1. Telomeres and telomerase
Telomerase is a cellular RNA-dependent DNA polymerase
enzyme containing two essential components, a telomerase
reverse transcriptase catalytic subunit (TERT, Gene ID 7015)
and a telomerase RNA template (TR or TERC, Gene ID
7012). Telomerase serves to maintain the tandem arrays of telo-
meric TTAGGG repeats at eukaryotic chromosome ends and
so counter the process of replication-associated telomere short-
ening. The crystallographic structure of the hTERT without li-
gand at the active site coded (3DU6) was used to explore the
binding afﬁnity of the newly designed analogs at the active siteFigure 1 Structures of telomerase inhibitors, BI(Gillis et al., 2008). However most of the designed compounds
showed promising recognition due to the high level of hydro-
philic characters with the presence of the core phenylene dia-
mine scaffold. Recently, Skordalakes et al. revealed the main
conserved residues at the hTERT binding to RNA–DNA li-
gands at the active site that give hand to intensely explore the
probability of comparing and competing hTERT selective
inhibitors at the ligand binding site (Mitchell et al., 2010).
Telomeres are the natural caps of linear eukaryotic chro-
mosomes. Telomeres are essential units that prevent the loss
of genetic information. One of the crucial features that distin-
guishes a cancer cell from a normal somatic cell is its ability to
divide indeﬁnitely. The hTERT is inactive in most somatic cells
and in contrast, approximately 85% of the most common can-
cers such as breast, prostate, lung, liver, pancreatic, and colon
cancers compensate for telomere shortening through over
expression of telomerase, allowing them to stably maintain
their telomeres and grow indeﬁnitely. As a corollary to this
mechanism telomerase is considered as a target not only for
cancer diagnosis but also for the development of novel thera-
peutic agents to suppress the hTERT expression as an ideal
strategy for the development of anticancer chemotherapeutics
that promote cell survival, enhance the suppression of oxida-
tive stress resistance cascade and induce tumor cell apoptosis
(Pe´rez-Rivero et al., 2008; Zhang and Ju, 2010; Cataldi, 2010).
1.2. Inhibitors targeting hTERT
Most antioxidant drugs control the oxidativeDNAdamage and
in turn demonstrate anticancer reactivity through many signal
pathways including selective inhibition of telomerase. The selec-
tive inhibition of telomerase can be effective in providing unique
treatments that discriminate between malignant and normal
cells to a high extent, avoiding many of the deleterious side-ef-
fects present with most current chemotherapeutic regimes
which rely on agents that kill dividing cells indiscriminately.
The synthetic inhibitor BIBR1532, 2-((E)-3-naphthalene-
2-yl-but-2-enoylamino)- benzoic acid, is a potent hTERT
inhibitor where aminobenzoic acid functional is considered
as an essential pharmacophore key for its reactivity (El-Daly
et al., 2005), (Fig. 1).
It is worth mentioning that EGCG and BROCA19 were
considered recently as remarkable lead compounds that per-
formed potent antioxidant and telomerase inhibitory effects
(Naasani et al., 2003; Burger et al., 2005).
Salophene metal analogs were considered as perfect scav-
enging agents that are able to diminish the elevated cellular
ROS that were over expressed and were implicated in cancer
initiation, promotion and progression, (Fig. 1) (Lange et al.,
2009).BR1532, EGCG, BROCA19 and Salophene.
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possess the pharmacophore functional keys to mimic the active
hTERT inhibitors mainly salicylamido and the schiff base
functional groups, (Fig. 1). Combining the inherent free radi-
cal scavenging activity of phenylene diamine with these phar-
macophore groups was expected to produce more active new
leads. Also, the thioureido functional group was known to
contribute to the enhancement of the antitumor activity (Pas-
colo et al., 2002).
The aim of this study is to locate novel synthetic lead com-
pounds and their in vitro testing as free radical scavenger with
promising anti DNA oxidative stress damage. Compounds
possessing such activity will be candidates for discriminatory
treatment of cancer by selectively invading cancer cells keeping
the normal cell with their regular vivacity.
2. Experimental section
2.1. General
All reagents and solvents were obtained from commercial sup-
pliers and were used without further puriﬁcation. Melting
points (C) were determined in open glass capillaries using
Branstead 9001 electrothermal melting point apparatus and
are uncorrected. NMR spectra were obtained on a Bruker AC
500 ultra shield NMR spectrometer (Fallanden, Switzerland)
at 500.13 MHz for 1H. The chemical shifts are expressed in d
(ppm) downﬁeld from tetramethylsilane (TMS) as internal
standard. Deuterio-chloroform (CDCl3) and deuteriodimethyl
sulfoxide (DMSO_d6) were used as solvents. Mass spectral
(MS) data were obtained on Perkin Elmer, Clarus 600 GC/
MS mass spectrometers. Thin layer chromatography was per-
formed on precoated (0.25 mm) silica gel GF254 plates (E.
Merck, Germany), compounds were detected with 254 nm UV
lamp. All modeling experiments were conducted with Hyper-
chem 6.03 package from Hypercube and Moelgro (Heydari
et al., 2008; Hyperchem, 1999).
2.2. Synthesis
To spotlight on the signiﬁcance of the pharmacophore func-
tional groups that were essential for selective recognition in
3KYL binding active sites and to achieve proper antioxidant
selectivity, Schemes 1 and 2 were used to prepare different ser-
ies of amido and thioureido-substituted phenylene diamine (2–
8) (Heydari et al., 2008).
In the present study, a series of new salicylamide phenylene
diamine analogs (3a–c and 7a–c) and their corresponding
benzamide (4a–c and 8a–c) were designed and synthesized
containing 1,2- and 1,3-phenylene diamine scaffolds. The
molecular modeling features of the designed compounds and
their recognition proﬁles with the binding active site of telome-
rase enzyme were investigated using the crystallography of
3KYL enzyme with the RNA–DNA ligands.
The synthesis of the target compounds is depicted in
Schemes 1 and 2. ortho-Phenylene diamine (1) was reacted
with amino protected analogs of methyl 4-Boc-aminosalicylate
and 3-Boc-aminobenzoyl chloride to give the corresponding
1,2-bis(4-bocaminosalicylamido)benzene and 1,2-bis(3-boca-
minobenzamido)benzene, they were deprotected by acidic
hydrolysis using HCl at room temperature for 1 h of stirringto afford the corresponding the amino analogs (2a,b) respec-
tively. Schiff’s base reaction of 2a,b with 3,4 dichlorobenzalde-
hyde gives the corresponding 3a and 4a respectively.
Condensation reaction of (2a,b) with 3,4,5-trimethoxybenzoyl
chloride affords the corresponding trimethoxybenzamide
derivatives of 1,2-phenylendiamines (3b and 4b). Phenylthio-
urea derivatives of 1,2-bis(4-aminosalicylamido)benzene and
of 1,2-bis(3-aminobenzamido)benzene (3c, 4c) were prepared
by reaction of two moles of phenylisocyanate with one mole
of (2a,b). 1,3-Phenylene diamine (5) was reacted with methyl
4-bocaminosalicylate and 3-bocaminobenzoyl chloride to give
the corresponding 1,3-bis(4-bocaminosalicylamido)benzene
and 1,3-bis(3-bocaminobenzamido)benzene, the protected
amido intermediates were deprotected by acidic hydrolysis
using HCl at room temperature for 1 h of stirring to afford
the corresponding amino analogs 6a, 6b. Schiff’s base reaction
of 6a,b with 3,4 dichlorobenzaldehyde gives the corresponding
7a and 8a respectively. Condensation reaction of (6a,b) with
3,4,5-trimethoxybenzoyl chloride affords the corresponding
trimethoxybenzamide derivatives of 1,2-bis -(4-aminosalicy-
lamido/3-benzamido)benzene (7b,8b). Phenylthiourea
derivatives of 1,3-bis -(4-aminosalicylamido/3-benzamido)ben-
zene (7c, 8c) were prepared by reaction of two moles of
phenylisocyanate with one mole of (6a,b).
2.2.1. N,N0-phenylenebis(4-amino-2-hydroxy benzamide) 2a,b,
6a,b* (MOLEGRO., 2009).
A solution of 0.2 mol of methyl ester of 4-boc-aminosalicylic
acid or 3-Boc-aminobenzoyl chloride, in ethanol was gradually
added to the appropriate phenylene diamine (1,5) in ethanol.
The reaction mixture was stirred and maintained at 90 C for
3 h. The reaction mixture was treated with HCl by stirring
for 1 h at room temperature, the corresponding deprotected
amino derivatives were neutralized, washed with cold water
and the formed precipitate was recrystallized from ethanol to
give 2a, 2b and 6a,b respectively.
2.2.1.1. N,N0-(1,2-phenylene)bis(4-amino-2-hydroxybenzam-
ide) 2a. 2a: Yield: 85% (ethanol); Mp: 225 C; 1H NMR
(CDCl3) d in ppm: d 5.50 (s, 2H, exchangeable-H, OH), 6.10
(brs, 4H, exchangeable-H, NH2), 7.80–8.00 (m, 10H, Ar-H),
9.30 (s, 2H, NH). MS m/e (379.14, 22%). Anal. (C20H18N4O4)
C, H, N.
2.2.1.2. N,N0-(1,3-phenylene)bis(4-amino-2-hydroxybenzam-
ide) 6a. 6a: Yield: 80% (ethanol); Mp: 115 C; 1H NMR
(CDCl3) d in ppm: d 5.30 (s, 2H, exchangeable-H, OH), 6.20
(brs, 4H, exchangeable-H, NH2), 7.70–7.80 (m, 10H, Ar-H),
9.20 (s, 2H, NH). MS m/e (380.14, 3.1%). Anal:
(C20H18N4O4) C, H, N.
2.2.1.3. N,N0-(1,3-phenylene-bis(4-aminobenzamide) 2b. Yield:
80% (ethanol); Mp: 110 C; 1H NMR (CDCl3) d in ppm: 5.80
(brs, 4H, exchangeable-H, NH2), 7.80–7.90 (m, 10H, Ar-H),
9.00 (s, 2H, NH). MS m/e (379.14, 22%). Anal. (C20H18N4O4)
C, H, N
2.2.2. N,N0-bis(4-((E)-(3,4-dichlorobezyledinyl-imino)-2-
hydroxy benzamido)benzene 3a, 7a
A solution of 0.2 mol of 3,4dichlorobezaldehyde in absolute
ethanol was gradually added to the appropriate aminobenz-
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a: methyl 4-Bocaminosalicylate,  HCl/ RT 1h
b: 3-Bocaminobenzoyl chloride,  HCl/ RT 1h
c: 3,4 dichlorobenzaldehyde                   
d: 3,4,5-trimethoxybenzoyl chloride
e: phenylisocyanate
Scheme 1 Synthesis of the target compounds 3 a,b,c–4a,b,c.
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mixture was stirred under reﬂux for 5 h. The reaction mix-
ture was evaporated, the residue was washed, neutralized
with diluted aqueous NaOH and the formed precipitate
was recrystallized from ethanol to give 3a and 7a
respectively.2.2.2.1. 1,2-Bis(4-((E)-(3,4-dichlorobezyledinylimino)-2-
hydroxybenzamido)benzene 3a. 3a: Yield: 75% (HCCl3); Mp:
190 C; 1H NMR (CDCl3) d in ppm: d 2.50 (s, 2H,CH=),
5.50 (s, 2H, exchangeable-H, OH), 7.80–8.00 (m, 16H, Ar-
H), 8.80 (brs, 2H, exchangeable-H, NH). MS m/e (694.07,
77.9%). Anal. (C34H26Cl4N4O4) C, H, N.
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b: 3-Bocaminobenzoyl chloride,  HCl/ RT 1h
c: 3,4 dichlorobenzaldehyde                   
d: 3,4,5-trimethoxybenzoyl chloride
e: phenylisocyanate
Scheme 2 Synthesis of the target compounds 7 a,b,c–8 a,b,c.
268 L. Abou-zeid, H.N. Baraka2.2.2.2. 1,3-Bis(4-((Z)-(3,4-dichlorobezyledinylimino)-2-
hydroxybenzamido)benzene 7a. 7a: Yield: 65% (HCCl3); Mp:
245 C; 1H NMR (CDCl3) d in ppm: d 2.40 (s, 2H,CH=),
5.20 (s, 2H, exchangeable-H, OH), 7.10–7.50 (m, 16H, Ar-
H), 9.00 (brs, 2H, exchangeable-H, NH). MS m/e (698.06,
47.7%). Anal. (C34H26Cl4N4O4) C, H, N.2.2.3. N,N0-bis(4-(3,4,5-trimethoxybezamido)-2-
hydroxybenzamido)benzene 3b,7b
To a stirred solution of 2a or 6a (0.01 mol) in absolute
ethanol (50 ml), 0.02 mol of 3,4,5-trimethoxybezoyl chloride
in acetone (50 ml) was added. The reaction mixture was
heated under reﬂux for 9 h, the separated solids were
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7b respectively.
2.2.3.1. 1,2-Bis(4-(3,4,5-trimethoxybezamido)-2-hydroxyben-
zamido)benzene 3b. 3b: Yield: 70% (EtAc); Mp: 105 C; 1H
NMR (CDCl3) d in ppm: d 3.85 (s, 18H,CH3), 5.35 (s, 2H,
exchangeable-H, OH), 7.10–7.80 (m, 14H, Ar-H), 9.10 (brs,
4H, exchangeable-H, NH). MS m/e (767.25, 45.6%). Anal.
(C40H38N4O12) C, H, N.
2.2.3.2. 1,3-Bis(4-(3,4,5-trimethoxybezamido)-2-hydroxyben-
zamido)benzene 7b. 7b: Yield: 60% (EtAc); Mp: 125 C; 1H
NMR (CDCl3) d in ppm: d 3.80 (s, 18H,CH3), 5.00 (s, 2H,
exchangeable-H, OH), 7.20–7.50 (m, 14H, Ar-H), 9.25 (brs,
4H, exchangeable-H, NH). MS m/e (768.26, 40.6%). Anal.
(C40H38N4O12) C, H, N.
2.2.4. N,N0-Bis(4-(phenylthioureido)-2-hydroxy
benzamido)benzene 3c,7c
To a stirred solution of 2a or 6a (0.01 mol) in absolute ethanol
(50 ml), 0.02 mol of phenylisocyanate in ethanol (50 ml) was
added. The reaction mixture was heated under reﬂux for 5 h,
the separated solids were ﬁltered, dried and recrystallized from
methanol to afford 3c, 7c respectively.
2.2.4.1. 1,2-Bis(4-(phenylthioureido)-2-hydroxy benzamido)
benzene 3c. 3c: Yield: 90% (Methanol); Mp: 280 C; 1H
NMR (CDCl3) d in ppm: d 4.10–4.25 (brs, 4H, exchange-
able-H, NH), 5.35 (s, 2H, exchangeable-H, OH), 7.00–7.50
(m, 20H, Ar-H), 9.10 (brs, 2H, exchangeable-H, NH). MS
m/e (649.16, 40.66%). Anal. (C34H28N6O4S2) C, H, N.
2.2.4.2. 1,3-Bis(4-(phenylthioureido)-2-hydroxy benzamido)
benzene 7c. 3c: Yield: 85% (Methanol); Mp: 175 C; 1H
NMR (CDCl3) d in ppm: d 4.00–4.15 (brs, 4H, exchange-
able-H, NH), 5.15 (s, 2H, exchangeable-H, OH), 6.80–7.50
(m, 20H, Ar-H), 9.00 (brs, 2H, exchangeable-H, NH). MS
m/e (650.16, 10.5%). Anal. (C34H28N6O4S2) C, H, N.
2.2.5. N,N0-bis(3-((E,Z)-(3,4-dichlorobezyledinylimino)
benzamido) benzene 4a, 8a
A solution of 0.2 mol of 3,4dichlorobezaldehyde in absolute
ethanol was gradually added to 0.2 mol of the appropriate
aminobenzamido derivatives (2b,6b) in acidic solution of etha-
nol. The reaction mixture was stirred under reﬂux for 7 h. The
reaction mixture was evaporated, the residue was washed, neu-
tralized with diluted aqueous NaOH and the formed precipi-
tate was recrystallized from ethanol to give 4a and 8a
respectively.
2.2.5.1. 1,2-Bis(3-((E)-(3,4-dichlorobezyledinylimino)-benz-
amido)benzene 4a. 4a: Yield: 65% (ethanol); Mp: 220 C; 1H
NMR (CDCl3) d in ppm: d 2.80 (s, 2H,CH=), 7.20–7.50 (m,
18H, Ar-H), 8.80 (brs, 2H, exchangeable-H, NH). MS m/e
(662.04, 47.6%). Anal. (C34H22Cl4N4O2) C, H, N
2.2.5.2. 1,3-Bis(3-((E)-(3,4-dichlorobezyledinylimino)-benz-
amido)benzene 8a. 8a: Yield: 75% (ethanol); Mp: 160 C; 1H
NMR (CDCl3) d in ppm: d 2.90 (s, 2H,CH=), 7.25–7.70 (m,
18H, Ar-H), 9.00 (brs, 2H, exchangeable-H, NH). MS m/e
(660.00, 5.2%). Anal. (C34H22Cl4N4O2) C, H, N.2.2.6. N,N0-bis(3-(3,4,5-trimethoxybezamido)-
benzamido)benzene 4b,8b
To a stirred solution of 2b or 6b (0.01 mol) in absolute ethanol
(50 ml), 0.02 mol of 3,4,5-trimethoxybezoyl chloride in acetone
(50 ml) was added. The reaction mixture was heated under
reﬂux for 6 h, the separated solids were ﬁltered, dried and
recrystallized from ethanol to afford 4b, 8b respectively.
2.2.6.1. 1,2-Bis(3-(3,4,5-trimethoxybezamido)-benzamido)ben-
zene 4b. 4b: Yield: 60% (ethanol); Mp: 200 C; 1H NMR
(CDCl3) d in ppm: d 3.45 (s, 18H,CH3), 7.60–7.75 (m, 16H,
Ar-H), 9.00 (brs, 4H, exchangeable-H, NH). MS m/e
(735.26, 45.1%). Anal. (C40H38N4O10) C, H, N.
2.2.6.2. 1,3-Bis(3-(3,4,5-trimethoxybezamido)-benzamido)ben-
zene 8b. 8b: Yield: 65% (ethanol); Mp: 155 C; 1H NMR
(CDCl3) d in ppm: d 3.70 (s, 18H,CH3), 7.50–7.80 (m, 16H,
Ar-H), 9.25 (brs, 4H, exchangeable-H, NH). MS m/e
(736.26, 25.1%). Anal. (C40H38N4O10) C, H, N.
2.2.7. N,N0-bis(3-(phenylthioureido)-benzamido) benzene 4c,8c
To a stirred solution of 2b or 6b (0.01 mol) in absolute ethanol
(50 ml), 0.02 mol of phenylisocyanate in ethanol (50 ml) was
added. The reaction mixture was heated under reﬂux for 5 h,
the separated solids were ﬁltered, dried and recrystallized from
methanol to afford 3c, 7c respectively.
2.2.7.1. 1,2-Bis(3-(phenylthioureido)-benzamido) benzene 4c.
4c: Yield: 70% (Methanol); Mp: 195 C; 1H NMR (CDCl3)
d in ppm: d 4.00–4.15 (brs, 4H, exchangeable-H, NH), 6.80–
7.40 (m, 22H, Ar-H), 9.15 (brs, 2H, exchangeable-H, NH).
MS m/e (617.17, 40.6%). Anal. (C34H28N6O2S2) C, H, N.
2.2.7.2. 1,3-Bis(3-(phenylthioureido)-benzamido) benzene 8c.
8c: Yield: 60% (Methanol); Mp: 265 C; 1H NMR (CDCl3)
d in ppm: d 4.00–4.20 (brs, 4H, exchangeable-H, NH), 7.00–
7.35 (m, 22H, Ar-H), 9.00 (brs, 2H, exchangeable-H, NH).
MS m/e (618.17, 10.5%). Anal. (C34H28N6O2S2) C, H, N.
2.3. ABTS antioxidant assay
ABTS [2, 2-azinobis(3-ethylbenzothiazoline 6-sulfonate] radi-
cal cation (ABTS+) scavenging activity was measured accord-
ing to the described methods. (Kalim et al., 2010; Re et al.,
1999) ABTS was dissolved in water to a 7 mM concentration
and the ABTS radical cation was produced by adding potas-
sium persulfate to a ﬁnal concentration of 2.45 mM. The com-
pletion of radical generation was obtained in the dark at room
temperature for 12–16 h. This solution was then diluted with
ethanol to adjust its absorbance at 734 nm to 0.50 ± 0.02. Dif-
ferent compounds were prepared by dissolving 1 mg each in
0.5 ml methanol and 0.5 ml phosphate buffer. To determine
the scavenging activity, 1 ml of diluted ABTS+ solution was
added to 50 ll of tested isolated compounds (or water for
the control), and the absorbance at 734 nm was measured
6 min after the initial mixing, using ethanol as the blank.
The percentage of inhibition was calculated by the equation:
Inhibition percentage ð%IPÞ ¼ ½Ac As=Ac  100
where Ac and As are the absorbance of the control and of
the tested samples respectively.
Table 1 Anti-oxidant assays by the ABTS method.
Method ABTS
Abs(control)  Abs(test)/Abs(control) · 100
No Compounds Absorbance of samples % Inhibition
Control of ABTS 0.491 0%
Ascorbic-acid 0.068 86.15%
1 3a 0.242 77.59%
2 3b 0.312 89.40%
3 3c 0.354 68.63%
4 4a 0.052 80.24%
5 4b 0.154 86.35%
6 4c 0.11 66.39%
7 7a 0.067 82.07%
8 7b 0.313 88.59%
9 7c 0.069 79.42%
10 8a 0.088 70.87%
11 8b 0.426 85.94%
12 8c 0.412 36.25%
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Molecular modeling studies of the new analogs in complex
with 3DU6 have been done to delineate features that differen-
tiate their mode of interaction. Starting coordinate of the
X-ray crystal structure of the 3KYL pdb enzyme in complex
is obtained from the RCSB Protein Data Bank of Brookhaven
National Laboratory (Mitchell et al., 2010). The energy mini-
mization was carried out using the molecular mechanics force
ﬁeld ‘‘AMBER’’. The energy-minimized structure was used for
molecular dynamics studies. The new analogs were constructed
from fragment libraries in the Hyperchem program (Heydari
et al., 2008). The partial atomic charges for each analog were
assigned with the semiempirical mechanical calculation meth-
od ‘‘AM1’’ implemented in Hyperchem 6.0. Conformational
search was performed around all the rotatable bonds with an
increment of 10 using conformational search module as
implemented in HyperChem 6.0. All the conformers were min-
imized until the RMS deviation was 0.01 kcal/mol A˚. For each
of the chosen analogs, energy minimizations (EM) were
performed using 1000 steps of the steepest descent, followed
by conjugate gradient minimization to a RMS energy gradient
of 0.01 kcal/mol A˚. The docking was carried out using a
ﬂexible ﬁtting module in MOLEGRO program (Hyperchem,
1999). Each inhibitor was geometrically optimized in the
enzyme-binding pocket.
3. Results and discussion
Reactive oxygen species (ROS) function as critical second
messenger in a variety of intracellular signaling pathways.
Thus, a defect or deﬁciency in the antioxidant defense system
and the excessive intracellular generation of ROS render a cell
oxidatively stressed. As a consequence, direct or indirect
involvement of ROS in numerous diseases has been
documented. The role of free radical oxidative damage in the
pathophysiology of human diseases is currently a topic of
considerable interest as free radical activity has been impli-
cated in a wide spectrum of clinical conditions, ranging from
cancer to atherosclerosis, stroke and neurodegenerative dis-
eases (Subramanian et al., 2010).
In the present study antioxidant capacity was measured in
response to ascorbic acid (86.15%). The antioxidant effect of
Compounds 3b and 7b showed highest antioxidant activities.
Compounds 3a, 4a, 7a and 8a showed moderate antioxidant
activities. Compounds 4c and 8c showed lowest antioxidant ef-
fects, (Table 1).
3.1. Molecular modeling study
Recently, the availability of a high resolution crystallographic
structure of the human telomerase complex with RNA–DNA
ligands affords the opportunity to expand the research target-
ing the small molecules with potential telomerase inhibition
activity as a marker of inhibiting the oxidative stress cascade
aiming to bring to light selective and safe cure of cancer.
Computational studies were performed to the designed
compounds (2–8) to examine their degree of recognition at
the binding active site with the conserved amino acids of the
3KYL telomerase enzyme in the presence of the DNA–RNA
ligands.In the binding model, the docked compounds, 3b and 7b, at
3KYL the RNA–DNA hybrid binding site showed hydrogen
bonding interactions with the critical key residues and compet-
itive interference with DNA and RNA by its U shaped conﬁg-
uration that conceals the DNA–RNA strands away from the
conserved amino acid residues at the primer grip of telomerase
enzyme with promising selective inhibition reactivity to
hTERT in the tumor cells, (Fig. 2).
3.2. Molecular dynamic study
The investigated compounds were subjected to molecular mod-
eling study to evaluate their recognition proﬁle at hTERT
binding-pocket in the presence of the RNA–DNA ligands
(Mitchell et al., 2010). The tertiary complex of hTERT,
RNA and DNA was used as a reference for modeling and
docking. At hTERT pocket, RNA strand formed bifurcated
H-bonding with the key residues Ile196, Val197, Gly309 and
Pro311, (Fig. 3) (Mitchell et al., 2010).
Fig. 2 showed the binding mode and residues involved in
the recognition of the most active compound 3b (86% inhibi-
tion of oxidation) docked and minimized in the hTERT con-
cealing the conserved aminoacids from interaction with
DNA or RNA strands at the binding pocket including the
most crucial aminoacid residues namely, Gly309, Pro311 and
Lys416.
3.3. Structure activity relationship (SAR)
3b and 7b showed an augment in the antioxidant activity due to
the presence of the hydroxyl group of the two salicylamide moi-
eties. Also the presence of trimethoxy groups at both terminal
phenyl rings enhanced the antioxidant actions. Also, com-
pounds 4b and 8b with trimethoxy groups as two terminals of
the benzamido moieties improve the antioxidant actions. How-
ever the absence of 2-hydroxyl groups (4b and 8b) abates to
some extent the hydrophilic recognition within the enzyme
binding site. Compounds 3a, 7a and 4a, 8a that have dichloro-
phenyl imino groups as a substitution of salycilamido- and
Figure 2 Molecular docking modeling of the most active free radical scavengers at the binding site of hTERT. Compounds, 3b and 7b, at
3KYL the RNA-DNA hybrid binding site showed hydrogen bonding interactions with the critical key residues and competitive
interference with DNA and RNA by its U shaped conﬁguration that conceals the DNA–RNA strands away from the conserved amino
acid residues at the primer grip of telomerase enzyme including the most crucial amino acid residues namely, Gly309, Pro311 and Lys416.
Figure 3 TERT–RNA template associations. The nucleotide
located at the 50 end of the RNA template (rC1) is coordinated by
Ile196 and Val197 of motif 2 and Gly309 of motif B0. rU2 interacts
with Pro311 of motif B0, and rG3 coordinates the backbone of
helix a15 via a water molecule (Wat18; red sphere), Ref 10.
Combating oxidative stress as a hallmark of cancer and aging 271benzamido- showed appropriate antioxidant activities (ranged
from 70% to 82%). Substitution with the phenyl group at both
terminals of the substituted thiourea benzamido of 1,2 and 1,3-
phenylene diamines resulted in a decrease in the antioxidant
effect of 4c and 8c due to the absence of donating functional
groups with the increase of hydrophobic interactions with the
surrounding conserved aliphatic amino acid residues (66.39%,
36.25%, respectively). On the contrary, the phenyl thiourea
group with salicylamido substituted 1,2 and 1,3-phenylene
diamines (3c and 7c) resulted in moderate antioxidant activities
due to the presence of the hydroxyl group at position C2, that
improves the hydrophilic/hydrophobic balance with the sur-
rounding hydrophilic amino acids leading to proper recognition
at the hTERT binding site (68.63%, 79.42% respectively).4. Conclusion
Compounds 3b,4b,7b,8b proved to be the most active free rad-
ical scavenger with percentage inhibition of oxidation range of
82–86%. Structure activity relationship studies revealed that,
the type of substituent at positions 4- of both sides of 1,3-phe-
nylene diamine with trimethoxy phenyl groups manipulates the
antioxidant activity comparable to the known natural antiox-
idant product, ascorbic acid.
Molecular modeling study was performed for the investi-
gated compounds to evaluate their recognition proﬁles at
hTERT binding-pocket. It is concluded that recognition with
key amino acid Gly309 and Pro311 is essential for binding
and biological activities.
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